Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.

Yewon NaSoo Wan KimIe Byung ParkSoo Jung ChoiSeungyoon NamJeong-Soo Im Dae Ho Lee

Published in: The Journal of clinical endocrinology and metabolism (2022)

DPP4i therapy in patients with diabetes was associated with a higher risk of liver cirrhosis and cancer, ESRD, and pancreatic cancer than TZD therapy and, except for liver cirrhosis, the risk of these outcomes was greater with DPP4i treatment than with non-DPP4i treatment.

Keyphrases

stem cells
chronic kidney disease
end stage renal disease
combination therapy
mesenchymal stem cells
replacement therapy
young adults
metabolic syndrome
glycemic control